Gerresheimer partners with RxCap to offer connected adherence solutions

EQS-News: Gerresheimer AG / Key word(s): Contract/Investment
Gerresheimer partners with RxCap to offer connected adherence solutions

29.04.2024 / 13:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Gerresheimer partners with RxCap to offer connected adherence solutions

  * Gerresheimer subsidiary Centor receives exclusive distribution rights
    for pharmacies in the U.S.

  * Adherence solutions enables pharmacies to offer remote therapeutic
    monitoring

* Digital therapy support leads to improved health outcomes

Düsseldorf/Berlin, Ohio, USA, April 29, 2024 - Gerresheimer, an innovative
systems and solutions provider and global partner for the pharma, biotech
and cosmetics industries, has entered into a partnership with the US digital
health company RxCap and acquired a minority stake. Under the terms of the
agreement, Gerresheimer's subsidiary Centor will receive the exclusive
distribution rights for pharmacies in the U.S. for adherence solutions by
RxCap, consisting of connected prescription vial closure devices and
complementary cloud-based software. Centor is the U.S. market leader in
prescription vials and is uniquely positioned to enable smart adherence
solutions through existing pharmacy workflows.

'The adherence solutions from RxCap is an ideal complement to the Centor
prescription vials', says Tony Haba, Senior Vice President North America at
Gerresheimer. 'Solutions for digital therapy support are a future growth
market for Gerresheimer. That is why we are increasingly offering our
customers innovative solutions consisting of connected primary packaging and
digital monitoring platforms. The partnership with RxCap is an excellent
example of this.'

'Our mission is to help people stay adherent to their medications and
improve their care outcomes,' says Sreeram Ramakrishnan, CEO of RxCap. 'By
partnering with Centor - an innovative market leader with strong relations
with pharmacies, we will be able to grow the number of patients we serve.
Moreover, Gerresheimer's expertise in primary packaging and access to
pharmacy leaders will enable us to develop additional adherence solutions
that amplify our impact.'

Minority shareholding and seat on the Board of Directors

As part of the partnership, Gerresheimer has acquired a minority stake in
RxCap in addition to the exclusive distribution rights for pharmacies in the
United States. Gerresheimer will also appoint a representative to RxCap's
Board of Directors.

Remote Therapeutic Monitoring

Patient adherence to medication is crucial for therapy outcome and can
prevent cost-intensive hospitalizations. Digital therapy support is becoming
increasingly important in this area, not only through body-worn sensors and
apps, but also through connected primary packaging and delivery systems and
medication adherence monitoring.

Under the partnership agreement Centor will offer RxCap's suite of connected
prescription vial closure devices and complementary cloud-based software to
pharmacies to help them monitor their patients' prescription adherence.
These solutions require no additional effort from the patient and can easily
be integrated with existing enterprise workflows to manage patient needs
effectively.

Using a cellular signal, the RxCap reports to the cloud-based software
platform when the prescription vial has been opened. Pharmacy staff can
easily and quickly assess whether the medication has been taken as
prescribed and remind the patient to take the medication by text message or
phone call.

This partnership will enable pharmacies to quickly launch adherence
solutions that can support patient's health journey more effectively, with
minimal additional investments in their workflow, and create new revenue
streams.

RxCap now available for U.S. pharmacies

The RxCap solution is now available for U.S. pharmacies and can be ordered
directly from Centor. Centor is thus expanding its product offering in the
U.S., positioning itself in the market for remote therapeutic monitoring and
also benefiting from recurring revenues while making significant impact on
patient health outcomes.

For order inquiries and questions, pharmacies can contact Centor at
prescription@centorrx.com.

About RxCap
RxCap, Inc. is a Boston-based prescription adherence technology corporation
enabling better patient outcomes and reducing health care costs. The company
supports healthcare enterprises in developing customized remote therapeutic
monitoring programs with a modular suite of enablement software, APIs, and
prescription adherence devices. By partnering with RxCap, enterprises can
quickly build revenue-generating RPM programs that integrate with their
existing care workflows.
www.rxcap.com

About Gerresheimer
Gerresheimer is an innovative systems and solutions provider and a global
partner for the pharma, biotech, and cosmetic industries. The company offers
a comprehensive portfolio of pharmaceutical containment solutions, drug
delivery systems and medical devices as well as solutions for the health
industry. The product range includes digital solutions for therapy support,
medication pumps, syringes, pens, auto-injectors, and inhalers as well as
vials, ampoules, tablet containers, dropper bottles, other bottles and more.
Gerresheimer ensures the safe delivery and reliable administration of drugs
to the patient. With 35 production sites in 16 countries in Europe, America
and Asia, Gerresheimer has a global presence and produces locally for
regional markets. With around 12,000 employees, the company generated
revenues of around EUR2bn in 2023. Gerresheimer AG is listed in the MDAX on
the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6).
www.gerresheimer.com


Contact Gerresheimer AG

   Media
   Jutta Lorberg Head of Corporate        Marion Stolzenwald Senior
   Communication T +49 211 6181 264       Manager Corporate Communication
   (1)jutta.lorberg@gerresheimer.com      T +49 172 2424185
   1.                                     (1)marion.stolzenwald@gerresheim
   mailto:jutta.lorberg@gerresheimer.c    er.com  1.
   om                                     mailto:marion.stolzenwald@gerres
                                          heimer.com
   Investor Relations
   Guido Pickert Vice President           Thomas Rosenke Senior Manager
   Investor Relations T +49 152 900       Investor Relations T: +49 211
   14145                                  6181-187
   (1)gerresheimer.ir@gerresheimer.com    (1)gerresheimer.ir@gerresheimer.
   1.                                     com  1.
   mailto:gerresheimer.ir@gerresheimer    mailto:gerresheimer.ir@gerreshei
   .com                                   mer.com

---------------------------------------------------------------------------

29.04.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        Gerresheimer AG
                   Klaus-Bungert-Str. 4
                   40468 Duesseldorf
                   Germany
   Phone:          +49-(0)211/61 81-00
   Fax:            +49-(0)211/61 81-121
   E-mail:         gerresheimer.ir@gerresheimer.com
   Internet:       http://www.gerresheimer.com
   ISIN:           DE000A0LD6E6
   WKN:            A0LD6E
   Indices:        MDAX (Aktie)
   Listed:         Regulated Market in Frankfurt (Prime Standard);
                   Regulated Unofficial Market in Berlin, Dusseldorf,
                   Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
   EQS News ID:    1891675

End of News EQS News Service
---------------------------------------------------------------------------

1891675 29.04.2024 CET/CEST